PECAM1 and cancer: However, the results obtained so far correlating quantitative variations in total CD31+ ECs with patients’ response to bevacizumab are conflicting [34], partially due to the existence of a substantial amount of nonmalignance‐related ECs in cancer patients’ peripheral circulation [12].